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Abstract
We recently reported that immature porcine Leydig cells express both somatostatin (SRIF) and
SRIF receptor type-2 (sst-2) transcripts. The present study was therefore undertaken to assess
whether SRIF might exert autocrine actions on these cells through sst2A receptor, one of the two
sst2 isoforms known to exert important neuroendocrine and endocrine functions. Using a
polyclonal antibody directed towards the C-terminal tail of the sst2A receptor subtype, receptor
immunoreactivity was detected in a subpopulation of Leydig cells and spermatogonia. To address
the physiological correlates of this expression we then studied the possible involvement of sst2
receptor in the regulation of testosterone secretion. Functional assays showed that the sst2 agonist
octreotide inhibited both basal and hCG-stimulated testosterone secretion by testosterone
pretreated Leydig cells. To assess whether sst2 receptor expression might be regulated by
testosterone, we performed a semi-quantitative RT-PCR analysis of sst2 mRNA expression in
Leydig cells cultured in the presence or in the absence of the androgen. A significant increase in
sst2 receptor transcripts was observed in testosterone-treated cells. Taken together, these data
suggest that SRIF can inhibit testosterone secretion through the sst2A receptor. The mechanism
of the local inhibitory actions of SRIF is probably autocrine since immature porcine Leydig cells
express SRIF itself and it might involve testosterone-induced increase of sst2 receptor expression
in immature Leydig cells.
Background
Regulatory peptide somatostatin (SRIF) displays a broad
tissue expression pattern. It modulates different cell func-
tions such as endocrine and exocrine secretions and pro-
liferation. These actions have been described in glands
and in the gastrointestinal and immune systems. They are
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mediated via six receptors (sst1, sst2A, sst2B, sst3, sst4,
sst5) encoded by five genes (sst1-5) located on distinct
chromosomes. Few commonly available ligands (e.g. oc-
treotide, MK 678 and RC 160) distinguish sst2/sst3/sst5-
from sst1/sst4-receptors since they bind to sst2/sst3/sst5
subfamily with subnanomolar affinity and are 1000-fold
less efficient on sst1/sst4 subfamily of receptors. Expres-
sion of different receptors is developmentally regulated in
a time- and tissue-specific manner. It is also influenced by
a variety of intra- and extra-cellular signals such as, for ex-
ample, second messengers and steroid hormones (for, re-
view, see [1]).
An accumulating body of evidence suggests that SRIF
might play the role of a local regulatory factor in the testis.
Indeed, SRIF has been identified in human [2], rat [3] and
pig [4] testes. In particular, the analysis of SRIF-immuno-
reactivity at the cellular level has indicated its presence in
spermatogonia and Leydig cells of immature pig testes [4].
Consistent with the hypothesis that the testis might be a
potential SRIF target, sst receptor transcripts have been
found in testes of different species. For example, the pres-
ence of sst3–sst5 transcripts has been reported in adult
human testes [5,6]. In addition, SRIF receptor transcripts
(sst1–sst3) have been visualized in adult rat testes where
germ- and Sertoli cells contain all three transcripts while
interstitial cells express only sst3 one [7]. In the immature
pig testes, sst2 receptor mRNAs have been localized to Ser-
toli cells, spermatogonia and Leydig cells [4,8].
The role of the SRIF/SRIF receptor regulatory loop remains
poorly understood in the mammalian testis. Recently
published data point to the involvement of SRIF/sst2 re-
ceptor interaction in the control of proliferation of Sertoli
cells [8] and spermatogonia [4]. Testosterone secretion by
Leydig cells has been reported to be modulated in a com-
plex manner after intra-testicular injection of SRIF in adult
rats [9,10] thus strongly suggesting existence of functional
SRIF receptors. However, the receptor subtypes involved
in SRIF-mediated modulation of testosterone secretion
have not been determined.
In this study, we searched for the presence of the sst2 re-
ceptor-protein in Leydig cells by a combined immunoblot
/ immunohistochemical approach and asked whether
these receptors might be involved in the regulation of tes-
tosterone secretion. The functional relevance of sst2 recep-
tors in immature porcine Leydig cells was analyzed by
assessing their involvement in the control of basal and
hCG-stimulated testosterone secretion. To approach a
possible transcriptional regulation of sst2 receptor expres-
sion by testosterone, sst2 mRNAs were measured by semi-
quantitative RT-PCR in the extracts obtained from cells
cultured in the presence or in the absence of testosterone.
On the whole, the results of these studies suggest that sst2
receptor might play a role in a "negative short loop feed-
back" by which testosterone regulates its own secretion in
Leydig cells.
Materials and Methods
Antibody preparation and Western blot analysis of sst2A 
immunoreactivity in the pig testis
The polyclonal R57 antibody was generated in New Zea-
land white rabbits against the peptide CERSDSKQDKSRL-
NETTETQRT after conjugation to keyhole limpet
hemocyanin via the NH2-terminal cysteine using m-male-
imidobenzoyl-N-hydroxysuccinimide. This sequence is
located in the C-terminal region of the rat sst2A receptor
and is conserved in the mouse, human [11] and pig [12]
receptor isoforms.
Testes used in this study were obtained from 3-week-old
pigs. At this perinatal age pigs are routinely castrated un-
der local anesthesia on the farms. The castration is per-
formed for the sake of body mass gain and meat taste
improvement in the standard chain of production for hu-
man consumption.
Testicular fragments were homogeneized in ultrapure 9 M
urea / 0.4% CHAPS (3-[3-chloramidopropyl]-dimethyl-
ammonio-1-propane-sulfonate)/ 5% mercaptoethanol
(all from Sigma, L'Isle d'Abeau, France) at a concentration
of 5 µg/5 µl, diluted 1:1 (vol / vol) in Laemmli-SDS sam-
ple buffer. The homogenates were electrophoresed on
10% SDS-polyacrylamide gels on a microscale [13]. After
transfer onto nitrocellulose membranes (Schleicher &
Schuell, PolyLabo, France), the membranes were blocked
for 2 hours in 5% non-fat dry milk in phosphate buffered
saline (PBS), incubated overnight with a polyclonal R57
primary antibody (1:2000 dilution) in non-fat dry 1%
milk in PBS / 0.05% Tween 80. After repeated washings,
the membranes were incubated with the alkaline phos-
phatase-coupled goat-anti-rabbit IgG in a 1:5000 dilution
(Jackson, Intechim-Interbiotech, France) and developed
in NBT / BCIP solution (5-bromo-4-chloro-o-indolyphos-
phate p-toluidin salt/ nitro blue tetrazolium).
Immunohistochemistry
Pig testes (n = 3) were fixed in 4% paraformaldehyde in
PBS (pH 7.4) and embedded in paraffin. Sections (5 µm-
thick) were mounted on positively charged glass slides
and thereafter deparaffinized, hydrated and treated for 20
min at 95 C in citric buffer (pH 6). After washings (2 × 5
min) in PBS containing 0.1% Tween-20, the sections were
preincubated 10 min at 37 C in peroxidase blocking rea-
gent (Envision+ kit, Dako, Trappes, France), washed and
incubated overnight at 4 C with R57 antibody in a 1:500
dilution. After two washings, the sections were incubated
(30 min, 37 C) with goat-anti-rabbit IgG attached to a per-
oxidase-conjugated polymer backbone (Envision+ kit,Reproductive Biology and Endocrinology 2003, 1 http://www.RBEj.com/content/1/1/19
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Dako, Trappes, France). At the end of the incubation peri-
od, the non-bound secondary antibody was washed and
sections were incubated 10 min at room temperature with
3-amino-9-ethylcarbazole to reveal a brown color at the
site of peroxydase activity. After an extensive wash, the nu-
clei were counterstained with Mayer's hematoxylin.
Leydig cell preparation and culture
Leydig cells were prepared from immature porcine testes
by collagenase (0.4 mg/ml, 90 min, 32 C) dispersion as
previously described [14]. Collagenase was removed by
centrifugation (200 × g for 10 min, 4 C). Resulting pellets
were resuspended in the medium and allowed to sedi-
ment successively for 5 and 15 min. The crude interstitial
cells were recovered from supernatants and Leydig cells
were separated by Percoll gradient centrifugation. The
content of Leydig cells in obtained preparations exceeded
90% as determined by histochemical 3β-hydroxy-steroid
dehydrogenase staining (data not shown). Purified Leydig
cells were plated in Petri dishes (60 × 15 mm, density of 5
× 106 cells/dish) for RNA extraction or in Falcon (Los An-
geles, CA) 24-multiwell plates (0.5 × 106 cells/well) for
testosterone assays. Cells were cultured at 32 C in a hu-
midified atmosphere of 5% CO2, 95% air in DMEM/
Ham's F-12 medium (1:1 vol/vol) containing sodium bi-
carbonate (1.2 mg/ml), 15 mM Hepes and gentamicin
(20 µg/ml). The medium was further supplemented with
insulin (2 µg/ml), transferrin (5 µg/ml) and α-tocopherol
(10 µg/ml).
Testosterone pretreatment and secretion assays
Leydig cells were pretreated with testosterone over 48 h
starting at day 4 after the beginning of the culture. The ex-
perimental conditions of testosterone pretreatment (150
ng/ml, 48 h) were chosen based on the previous studies
from our laboratory targeting the androgen receptors of
porcine Sertoli cells [15]. The assumption that a similar
testosterone concentration may be used to target andro-
gen receptors present on these two cell types was based on
the previous findings demonstrating the presence of one
single type of androgen receptor in the whole-testis prep-
arations obtained from the immature pigs of the same
perinatal age as those used in our study [16]. By conse-
quence, androgen receptors expressed by any testicular
cell type are obviously identical and can be efficiently tar-
geted by the same testosterone concentration.
At the end of the pretreatment period, cells were washed
and incubated in the fresh medium (1 h, 32 C) three
times. Indeed, in the preliminary set of experiments we
successively washed and then incubated cells (32 C, 1 h)
to allow a dissociation of the residual testosterone possi-
bly adsorbed on the cell surface. Testosterone concentra-
tion was monitored in the culture supernatants obtained
at the end of the 1-hour incubation periods at 32 C. The
number of washings was finally set at 3 since testosterone
was undetectable in the supernatants of cultures obtained
after 3 rounds of washings / incubations.
Secretion assays, in which the accumulation of secreted
testosterone was measured in either basal or hCG-stimu-
lated conditions, were performed at day 6 of culture. In-
deed, immature porcine Leydig cells in primary culture
retain their full steroidogenic capacity (i.e. they respond
to hCG stimulation by high and stable testosterone secre-
tion) between day 2 and 6 of culture [17]. A 3 h-period of
stimulation by hCG (CR 127 13450 IU/mg obtained from
Dr A.F. Parlow, NHPP, Torrance, CA) was chosen since, in
this culture model, the accumulation of unconjugated
steroids upon hCG addition is linear only during the first
4 h of treatment [18]. Testosterone levels were measured
in the culture medium by using a previously reported spe-
cific RIA [19].
RT-PCR analysis of sst2 receptor expression
Cultured Leydig cells or testis fragments were washed with
PBS solution and total RNAs were extracted with TRIzol
reagent (Gibco BRL, Cergy Pontoise, France) according to
the manufacturer's instructions.
For RT-PCR analysis, 3 µg of total RNA was reverse-tran-
scribed in 10 µl of reaction mixture containing 200 µM
dNTPs, 10 U/ml of Moloney Murine Leukemia Virus
(MMLV) reverse transcriptase, 0.01 M dithiothreitol
(DTT) and 5 µM random hexamer primers in 20 mM Tris-
HCl buffer for 60 min at 37 C, followed by heating at 100
C for 5 min.
One-tenth (2 µl) of the first strand of cDNA synthesis re-
action mixture was added to PCR buffer (100 mM Tris)
containing 0.2 mM dNTP and 1.25 U Taq DNA polymer-
ase in a total volume of 50 µl. GAPDH and sst2 primer se-
quences, concentrations and amplification conditions
have been previously detailed elsewhere [8].
For semi-quantitative analysis of sst2 receptor expression,
2 µl of the RT reaction mixture from each sample were am-
plified with either sst2 [8] or β-actin [4] primers,
[α33P]dATP (0.75 µCi), Taq polymerase (0.01 U/µl),
dNTPs (100 µM), MgCl2 (1.5 mM) and buffer (50 mM
Tris-HCl) according to the already reported conditions
[4,8]. The PCR amplification was carried out using Trio-
thermoblock (Biometra, Kontron Instruments, Cham-
pagne au Mont d'Or, France) for 5 min of initial denatur-
ation at 94 C, followed by 20 cycles of amplification for β-
actin (94 C for 30 s; 61 C for 60 s; 72 C for 60 s) or 25 cy-
cles for sst2 (94 C for 30 s; 60 C for 60 s; 72 C for 60 s).
Final elongation was achieved at 72 C for 5 min.Reproductive Biology and Endocrinology 2003, 1 http://www.RBEj.com/content/1/1/19
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The number of PCR cycles was determined in preliminary
experiments by performing from 20 to 35 and 15 to 30
amplification reactions for sst2 and β-actin, respectively.
Amplification for sst2 and β-actin was linear up to 30 and
25 cycles, respectively (data not shown). In order to be
sure that the amplification products to be analyzed were
obtained during the linear phase of reaction, the number
of PCR cycles was fixed to the last 5-cycle increment before
saturation was reached (i.e. to 25 and 20 cycles for sst2
and  β-actin, respectively). For negative controls, cDNA
was replaced by water to confirm the absence of any reac-
tive contamination.
PCR products were resolved by 8% polyacrylamide gel
electrophoresis. Products of amplification were visualized
by using Kodak X-Omat S films (Eastman Kodak, Roches-
ter, NY). The intensities of the autoradiographic bands
were measured by densitometric scanning using the Intel-
ligent quantifier (Bioimage, Omni Media scanner XRS).
The results correspond to the optical densities (OD) of au-
toradiograms relative to three different RT-PCRs per-
formed with RNAs extracted from Leydig cells from three
independent cultures. The ODs corresponding to sst2 and
β-actin mRNA expression in each individual sample were
expressed in arbitrary units as a ratio of sst2 over β-actin
densitometric intensities.
Data analysis
If not otherwise specified, data are presented as the mean
± SEM of triplicate determinations performed in at least
three independent experiments carried out with different
cell preparations or cell cultures. Statistical significance of
the differences observed between experimental groups
was determined by one-way ANOVA using InStat (Graph
PAD Software) computer program. Post-hoc comparisons
between treatment group means were made with the Bon-
ferroni test for multiple comparisons. In sst2 receptor ex-
pression assays, the significance of the difference between
the control- and testosterone treated groups was assessed
by two-tailed t-test. Differences are considered as signifi-
cant if p < 0.05.
Results
sst2A receptor expression in testicular homogenates and 
extracts from cultured Leydig cells
Western blot analysis was performed with R57 antibody
on the whole soluble protein extracts obtained from testes
of 3-week-old pigs. An R57-immunoreactive protein with
an approximate molecular weight of 55 kDa (Fig. 1A, first
lane) was identified. The staining of the immunoreactive
protein was blocked by 1 µM antigenic peptide (Fig. 1A,
second lane). No immunoreactive protein was detected
with preimmune serum (Fig. 1A, third lane).
Parallel RT-PCR analysis with sst2-specific primers
showed that a fragment of an expected size (i.e. 415 bp)
could be amplified when cDNAs obtained from total RNA
extracts (prepared from the same testes as those used for
protein extraction) were used as a template (Fig. 1B, lane
"T+"). A product of an identical size was amplified from
cDNAs corresponding to RNA extracts obtained from cul-
tured Leydig cells (Fig. 1B, lane "L+"). The identities of the
amplified fragments were checked by automated DNA se-
quencing using ABI Prism 310 Genetic Analyzer (Applied
Biosystems, Courtaboeuf, France) (data not shown). The
absence of any contamination was confirmed by the fact
that no amplification products were obtained when cDNA
template was replaced by water (data not shown). Similar-
ly, no amplification occured in PCRs when they were per-
formed after RT reactions in which RNAs has been
processed without addition of MMLV (Fig. 1B, lanes "L-"
and "T-").
sst2A receptor expression in Leydig cells in situ
Expression of sst2 receptor protein was studied by immu-
nohistochemistry on tissue sections from immature pigs.
Positive immunostaining with R57 antibody was ob-
served in both intratubular and interstitial compartments
(Fig. 2a,2d,2e,2f). Detailed cytological analysis allowed us
to attribute this immunoreactivity to spermatogonia and
Leydig cells. However, both cell types immunostained
heterogeneously, i.e. they showed varying (from low to
strong) intensity of labeling (Fig. 2a,2d,2e,2f). The ob-
served immunostaining was specific because it was abol-
ished in the presence of 1 µM of exogenously added
antigenic peptide (Fig. 2b). Testicular sections processed
without incubation with R57 antibody displayed no im-
munoreactivity thus excluding any artifactual labeling
(Fig. 2c).
Functional involvement of sst2 receptor in the regulation 
of testosterone secretion
To approach the functional relevance of sst2 receptors of
Leydig cells, we first assessed their possible involvement
in the regulation of basal testosterone secretion. Addition
of a relatively selective sst2 agonist octreotide (Novartis,
Basel, Switzerland) had no significant effect on testoster-
one secretion (Fig. 3A).
We next sought to determine whether the testosterone
pretreatment (150 ng/ml, 48 h) could modify the octre-
otide actions on testosterone secretion by immature por-
cine Leydig cells. Interestingly, testosterone pretreatment
by itself (i.e. in the absence of octreotide) greatly (4- to 5-
fold) increased the capacity of immature Leydig cells to se-
crete testosterone (Fig. 3A: p < 0.001 for "-T" versus "+T"
at octreotide concentration "0"). The observed increase in
testosterone secretion by pretreated cells cannot be attrib-
uted to the assay contamination by exogenousReproductive Biology and Endocrinology 2003, 1 http://www.RBEj.com/content/1/1/19
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Figure 1
The whole testicular extracts of immature porcine testes contain both sst2A receptor protein (A) and transcript (B). (A) 
Western blot analysis of sst2A receptor immunoreactivity in soluble protein extracts (100 µg) separated by 10 % SDS-PAGE. 
After the electrotransfer of proteins, the corresponding nitrocellulose membrane was divided into three parts. Two parts 
were immunoblotted with either R57 antibody alone (first lane: "immune") or in the presence of the antigenic peptide (second 
lane: "preadsorbed"). The third part was incubated in parallel with the preimmune serum (third lane: "preimmune"). Molecular 
mass (in kDa) is indicated by the arrow. (B) Amplification products obtained in PCR reaction with sst2-specific primers. Tem-
plates used in the reaction are: cDNA corresponding to the whole testicular tissue (lane "T+") and cultured Leydig cells (lane 
"L+") obtained in the RT reactions as described in Materials and Methods; mRNAs obtained from the whole testicular tissue 
(lane "T-") and cultured Leydig cells (lane "L-") and processed according to the same RT protocol as the former samples but 
without the addition of MMLV. The size (in bp) of DNA fragments is given by the lane "M". The lower panel shows the amplifi-
cation of internal standard GAPDH-fragments in the corresponding samples.
B
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testosterone added in order to perform culture pretreat-
ment (see Testosterone pretreatment and secretion assays in
Materials and Methods). However, a pretreatment of Ley-
dig cells with testosterone revealed a capacity of octreotide
to inhibit testosterone secretion in a dose-dependent
manner (F = 17.73, p < 0.001 according to the global one-
way ANOVA as compared to the testosterone pretreated
cells incubated in the absence of octreotide). The maximal
inhibitory effect was achieved at octreotide concentration
range from 1 nM to 1 µM (Fig. 3A). In addition, a signifi-
cant difference in testosterone secretion was seen between
testosterone-treated and untreated Leydig cells for the cul-
tures carried out in the presence of the low (p < 0.001 for
1–10 pM and p < 0.05 for 100 pM) octreotide concentra-
tions (Fig. 3A).
Further experiments were designed to assess the capacity
of SRIF agonist to inhibit hCG-stimulated testosterone se-
cretion. To do that, Leydig cell cultures were simultane-
ously incubated with octreotide, added at the
concentration eliciting a maximal inhibitory effect in ba-
sal conditions (1 µM), and increasing concentrations of
hCG (0.065–4 ng/ml). The results obtained in these ex-
periments showed that in the presence of octreotide, hCG
could still elicit a slight increase in testosterone secretion
although, for all hCG concentrations tested, this increase
was not significantly different from the controls incubated
without hCG addition (Fig. 3B). By contrast, in the ab-
sence of octreotide, hCG triggered a significant increase of
testosterone secretion even at the lowest (0.065 ng/ml)
concentration tested (Fig. 3B). Besides, the analysis of the
inhibitory actions of octreotide on hCG-mediated induc-
tion of testosterone secretion point to a statistically signif-
icant difference between octreotide treated and untreated
cells at hCG concentrations greater than 0.5 ng/ml (Fig.
3B).
The effects of testosterone pretreatment (150 ng/ml, 48 h)
on octreotide-mediated inhibition of testosterone secre-
tion were also studied in hCG-stimulated conditions.
Similarly as in cell cultures pretreated with testosterone
and assayed in basal conditions, testosterone pretreat-
ment per se increased its own secretion by hCG-stimulat-
ed Leydig cells. Moreover, such an increase was additive to
Figure 2
sst2A-like immunoreactivity on formalin-fixed, paraffin-embedded testis sections. Tissue sections were incubated with R57 
anti-sst2A antibody (1:500 dilution) alone (a) or in the presence of exogenously added antigenic peptide (b). Negative control 
consisted in staining procedure in which anti-sst2A antibody was omitted (c). Magnified frame from the middle of (a) is shown 
in (d) with arrow-heads pointing to immuno-negative spermatogonia. Magnified field from the bottom right in (d) is shown in 
(e) with simple arrows pointing to the immuno-labeled Leydig cells; dashed arrows point to immuno-negative Leydig cells. (f) 
another section plane with double arrows pointing to immuno-labeled spermatogonia in the interior of seminiferous tubule. 
Note the staining heterogeneity of both Leydig cells and spermatogonia (d-f). Scale bars: A-C = 100 µM; D = 50 µM; E-F = 25 
µM.Reproductive Biology and Endocrinology 2003, 1 http://www.RBEj.com/content/1/1/19
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Figure 3
Functional involvement of sst2A receptor in the regulation of basal (A) and hCG-stimulated (B, C) testosterone secretion by 
immature porcine Leydig cells pretreated (A, C) or not (A, B) with testosterone. (A) Leydig cells were pretreated (48 h) in the 
absence of 150 ng/ml testosterone ("-T") or in its presence ("+T"). After 3 rounds of successive washings / incubations (1 h, 32 
C), cells were incubated for the additional 3 h in the absence or in the presence of octreotide in the concentration range from 
1 pM to 1 µM. At the end of the incubation period cell supernatans were collected for RIA determination of the secreted tes-
tosterone. *: p < 0.05 for testosterone secretion measured in the presence of the octreotide compared to that measured in its 
absence in testosterone pretreated group. b: p < 0.01; c: p < 0.001 for comparisons between testosterone-pretreated and tes-
tosterone-untreated cells at a given octreotide concentration. (B) Leydig cells were incubated (3 h) in the presence of the 
increasing concentrations of hCG (0.065–4 ng/ml range) and either in the absence ("-oct") or in the presence ("+oct") of 1 µM 
octreotide. Testosterone secretion was measured by RIA in the relevant supernatants. *: p < 0.05; **: p < 0.01 for hCG-stimu-
lated testosterone secretion versus that measured in its absence. a: p < 0.05 for comparisons between octreotide-treated and 
untreated cells at a given octreotide concentration. (C) Leydig cells were pretreated with testosterone (150 ng / ml, 48 h), 
then washed as in (A) and incubated for additional 3 h in the presence of the increasing concentrations of hCG (0.065–4 ng/ml 
range) and either in the absence ("-oct") or in the presence ("+oct") of 1 µM octreotide. Testosterone secretion was measured 
by RIA in the relevant supernatants. *: p < 0.05; **: p < 0.01 for hCG-stimulated testosterone secretion versus that measured 
in its absence. c: p < 0.001 for comparisons between octreotide-treated and untreated cells at a given hCG concentration.
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hCG stimulation (Table 1). Thus, hCG-stimulated testo-
sterone secretion in testosterone-pretreated cells was
about twice that measured in untreated cells at all (0.065–
4 ng/ml) hCG concentrations tested (Table 1). In these ex-
perimental conditions, octreotide added at 1 µM concen-
tration, was able to significantly (p < 0.001 at all hCG
concentrations tested for comparisons between "-oct" and
"+oct") inhibit the hCG-triggered increase of testosterone
secretion by testosterone-pretreated Leydig cells (Fig. 3C).
Moreover, after testosterone pretreatment, the octreotide
could completely prevent hCG-induced increase in testo-
sterone secretion at all hCG concentrations tested (Fig.
3C).
Modulation of sst2 receptor expression by testosterone
In order to address the mechanism of the observed inhib-
itory actions of octreotide that were revealed by testoster-
one pretreatment, we analyzed the expression of sst2
receptor transcripts in control and testosterone-pretreated
Leydig cells. Testosterone treatment of these cells in the
identical conditions as those used in functional assays
(i.e. 150 ng/ml over 48 h) showed that the quantity of sst2
transcripts double in pretreated cells (Fig. 4).
Discussion
The data presented in this study show that SRIF inhibits
both basal- and hGC-stimulated testosterone secretions
by immature porcine Leydig cells. However, testosterone
pretreatment was necessary to reveal this inhibition in ba-
sal conditions whereas in hCG-stimulated conditions, the
inhibitory effects of SRIF on testosterone secretion were
detectable in the absence of testosterone pretreatment but
were more pronounced in testosterone pretreated Leydig
cells. Induction of sst2 receptor expression by testosterone
might be one of the underlying molecular mechanisms re-
sponsible for the inhibition of testosterone secretion by
SRIF. These findings, combined with the results we have
previously reported on SRIF-mediated inhibition of sper-
matogonia- and Sertoli cell-proliferation [4,8], bring new
arguments for the inhibitory role of SRIF in the control of
testicular cell functions. Moreover, this work provides fur-
ther insights on the importance of SRIF in testicular cell-
cell interactions and on its mode of actions. Thus, given
the previously documented SRIF-immunoreactivity of im-
mature porcine Leydig cells [4], the presence of the func-
tional sst2 receptors on Leydig cells shown here point to
the autocrine actions of SRIF on Leydig cells. These intra-
testicular actions are additional to the already suggested
paracrine actions of SRIF on Sertoli cells and its autocrine
actions on spermatogonia [4].
The culture conditions used here were validated by the ob-
served low basal testosterone secretion [20] and induction
of testosterone secretion by hCG in the same range of
magnitude as that reported previously for the similar cul-
ture conditions [17,21]. The maximal inhibition of testo-
sterone secretion by octreotide is achieved at nanomolar
concentration, in agreement with subnanomolar affinity
of octreotide on sst2 receptor subtype [1]. Western blot as-
says allowed us to identify an sst2A-immunoreactive pro-
tein with an apparent mass of approximately 55 kDa, in
agreement with the range of 60 to 110 kDa reported for
the molecular mass of previously identified sst2 receptors,
depending on the cell and tissue types studied [22–27].
Similarly, the size of the fragments obtained in our RT-
PCR from Leydig cell RNA extracts with the same sst2A-
specific primers is identical to those previously reported in
different cell types of immature porcine testes [4,8] and in
human tissues [28].
Our data show that SRIF inhibits both basal and stimulat-
ed testosterone secretion by Leydig cells. However, such
inhibition can be evidenced only when the level of testo-
sterone secretion was elevated either by testosterone
Table 1: Stimulation of testosterone secretion by hCG in control and testosterone-pretreated Leydig cellsa.
Secreted tesosterone (nM)
hCG (ng/ml) control pretreated
0 0.060 ± 0.0001b 0.250 ± 0.013*
0.065 0.200 ± 0.003d 0.400 ± 0.004*
0.125 0.280 ± 0.034c 0.450 ± 0.024*
0.250 0.330 ± 0.028d 0.630 ± 0.026c,*
0.500 0.290 ± 0.030d 0.730 ± 0.052c,*
1 0.370 ± 0.035d 0.630 ± 0.034c,*
2 0.500 ± 0.052e 0.960 ± 0.052d,*
4 0.460 ± 0.043e 0.890 ± 0.061d,*
a pretreatment conditions are given in "Materials and Methods". bdata are expressed as mean ± SEM. c,d,etestosterone secretion significantly (c:p < 
0.05; d:p < 0.01; e:p < 0.001) higher in the presence of hCG than in its absence in either control- or testosterone-pretreated cells *testosterone 
secretion significantly (p < 0.01) higher for the same hCG concentration in testosterone-pretreated than control cells.Reproductive Biology and Endocrinology 2003, 1 http://www.RBEj.com/content/1/1/19
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Figure 4
Testosterone pretreatment (150 ng/ml, 48 h) triggers an increase in sst2A receptor mRNA expression. At the upper panel are 
shown the representative autoradiograms from one experiment. At the lower panel are depicted the histograms representing 
the mean ± SEM of optical densities (ODs) measured on corresponding autoradiograms for each determination performed in 
three independent experiments (see "Materials and Methods"). C = control; T = testosterone-pretreated (150 ng/ml; 48 h); **: 
p < 0.01 versus "C".
0
0,25
0,5
0,75
(
s
s
t
2
/
ß
-
a
c
t
i
n
)
 
m
R
N
A
 
(
O
D
)
CT
sst2
ß-actin
**Reproductive Biology and Endocrinology 2003, 1 http://www.RBEj.com/content/1/1/19
Page 10 of 11
(page number not for citation purposes)
pretreatment alone or in combination with hCG stimula-
tion. Besides, the mechanism of the testosterone-induced
testosterone secretion in immature pig testes was beyond
the scope of our study and remains unknown. However, it
seems clear that testosterone has different actions on Ley-
dig cells depending on the developmental stage: it increas-
es its own secretion in immature Leydig cells [[29,30],
present study] whereas in adult cells it has rather inhibito-
ry actions via a "short-loop negative feed-back" mecha-
nism [31].
The fact that SRIF-mediated inhibition of testosterone se-
cretion could be revealed only in the context of the elevat-
ed testosterone secretion is probably related to the low
level of testosterone secretion by immature Leydig cells in
the absence of hCG [20] or testosterone pretreatment.
Such a low basal rate of testosterone secretion might
explain why the inhibitory actions of SRIF, expected to
further lower the already low basal secretion, were not de-
tectable. Indeed, during the initial phase of this work we
took advantage of the immature porcine Leydig cells mod-
el since, based on the in vivo data [9,10], SRIF actions on
testosterone secretion were expected to be rather stimula-
tory. Consequently, the possible SRIF-mediated altera-
tions of testosterone secretion would be more accurately
measured in the presence of the low basal level of testo-
sterone secretion. The obtained results are, however, in
contrast with that hypothesis. The differences between
SRIF actions observed between previous [9,10] and
present studies might be related to different species (rat
versus pig) since in all three studies immature animals
were used. Nevertheless, the inhibitory actions of SRIF on
the testosterone secretion observed in the present study
are in agreement with the data relative to SRIF-induced in-
hibition of the majority of hormonal secretion studied so
far (for review, see [1]).
Our findings on testosterone-mediated sst2 receptor
mRNA induction represent a contribution to the under-
standing of the molecular mechanisms by which SRIF
receptor expression is regulated. Indeed, transcriptional
regulation of SRIF receptors by various hormones has
been previously documented. For example, thyroid hor-
mone triggers a specific induction of mRNA for sst1 and
sst5 in murine thyrotropic tumors [32]. Steroid hormones
also modulate SRIF receptor expression. For example, es-
tradiol up-regulates mRNA for sst2 receptor in human
breast cancer cells [33] and in rat pituitary cells [34]. In ad-
dition, in the latter cells estradiol increases sst3 mRNA ex-
pression and inhibits sst1, sst4 and sst5 expression [34].
Both positive and negative regulations of sst1 and sst2
receptors by glucocorticoids have been reported [35]. All
these hormones (including testosterone) have in com-
mon the transduction via nuclear receptors that directly
influence the expression of the target genes. Consistently,
relevant response elements for some of these hormones
have been identified in promoters of sst receptor genes
(for review, see [1]). Further experiments are now needed
in order to assess the presence of the consensus androgen-
binding element (ARE) in the promoter of sst2 receptor
gene. Interestingly, testosterone-induced up-regulation of
sst1 receptor mRNAs has been reported in the rat anterior
pituitary [36].
There is general agreement that many local factors such as
cytokines and growth factors are implicated in negative
regulation of testosterone secretion (for review, see [37]).
However, the molecular mechanisms by which high testo-
sterone levels are linked to the induction of these factors
are not completely characterized. The findings presented
here extend the list of local factors capable of inhibiting
testosterone secretion. They also offer a possible
molecular basis for the local, SRIF-mediated relay of high
testosterone levels by which this androgen might inhibit
its own secretion through a "short loop negative feed-
back" inhibition of testosterone secretion [31]. Previously
reported testosterone capacity to increase SRIF expression
(for review, see [1]) is consistent with the latter hypothesis
and the model of immature porcine Leydig cells in culture
allows now to test it directly. Demonstration of such an
intra-testicular regulation would be reminiscent of the re-
ported intra-hypothalamic "short loop negative feed-
back" inhibition of GH secretion through GH-induced in-
crease of sst1 receptor mRNA [38].
Acknowledgments
We are indebted to Drs Stolz (Novartis, Basel, Switzerland) and Parlow 
(NHPP, Torrance, CA) for the generous gift of octreotide and hCG, 
respectively.
We should like to thank Dr A. Gougeon and Dr S. Bauer for their precious 
help on immunohistochemistry, Christelle El Ghamrawy for help during the 
setting-up of semi-quantitative RT-PCR assays, Mrs G. Thoiron for the Eng-
lish translation and the farmer, Mr. P. Bouteille, for providing us with por-
cine testes at castration.
References
1. Patel YC Somatostatin and its receptor family.  Frontiers in
Neuroendocrinology 1999, 20:157-198
2. Sasaki A and Yoshinaga K Immunoreactive somatostatin in
male reproductive system in humans. J Clin Endocrinol Metab
1989, 68:996-999
3. Pekary AE, Yamada T, Sharp B, Bhasin S, Swerdlof RS and Hershman
JM  Somatostatin-14 and -28 in the rat male reproductive
system. Life Sci 1984, 34:939-945
4. Goddard I, Bauer S, Gougeon A, Lopez F, Giannetti N, Susini C,
Benahmed M and Krantic S Somatostatin inhibits Stem Cell Fac-
tor Messenger RNA expression by Sertoli cells and Stem
Cell Factor-Induced DNA synthesis in isolated seminiferous
tubules. Biol Reprod 2001, 65:1732-1742
5. Baou N, Bouras M, Droz JP, Benahmed M and Krantic S Evidence for
a selective loss of somatostatin receptor subtype expression
in male germ cell tumors of seminoma type. Carcinogenesis
2000, 21:805-810
6 . B a o u  N ,  B o u r a s  M ,  D r o z  J P ,  D u t r i e u x - B e r g e r  N ,  B o u v i e r  R ,
Benahmed M and Krantic S Somatostatin receptor expression
profile as a potential criterion for discrimination betweenPublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Reproductive Biology and Endocrinology 2003, 1 http://www.RBEj.com/content/1/1/19
Page 11 of 11
(page number not for citation purposes)
seminoma and non-seminoma testiculatr tumors. Cancer De-
tection and Prevention 2001, 25:446-453
7. Zhu LJ, Krempels K, Bardin CW, O'Carroll AM and Mezey E The lo-
calization of messenger ribonucleic acids for somatostatin
receptors 1, 2, and 3 in rat testis. Endocrinology 1998, 139:350-
357
8. Krantic S and Benahmed M Somatostatin inhibits FSH-induced
adenylyl cyclase activity and proliferation in immature por-
cine Sertoli cell via sst2 receptor. Biol Reprod 2000, 62:1835-
1843
9. Gerendai I, Csaba Z and Csernus V Effect of intratesticular ad-
ministration of somatostatin on testicular function in imma-
ture and adult rats. Life Sciences 1996, 59:859-866
10. Gerendai I Fine-tuning control of testicular function. Neurobiol-
ogy 1997, 5:347-359
11. Kluxen F, Bruns C and Lubbert H Expression cloning of a rat
brain somatostatin receptor cDNA. Proc Natl Acad Sci 1992,
89:4618-4622
12. Matsumoto K, Yokogoshi Y, Fujinaka Y, Zhang C and Saito S Molec-
ular cloning and sequencing of porcine somatostatin recep-
tor 2. Biochem Biophys Res Commun 1994, 199:298-305
13. van Boxberg Y Protein analysis on two-dimensional polyacry-
lamide gels in the femtogram range: use of a new sulfur-la-
beling reagent. Anal Biochem 1988, 169:372-375
14. Benahmed M, Chauvin MA, Morera AM and DePeretti E Somato-
medin C/insulin-like growth factor 1 is a possible intratestic-
ular regulator of Leydig cell activity. Mol Cell Endocrinol 1987,
50:69-77
15. Benbrahim-Tallaa L, Tabone E, Tosser-Klopp G, Hatey F and
Benahmed M Glutathione S-transferase alpha expressed in
porcine Sertoli cells is under the control of follicle-stimulat-
ing hormone and testosterone. Biol Reprod 2002, 66:1734-1742
16. Tripepi S, Carelli A, Perrotta E, Brunelli E, Tavolaro R, Facciolo RM
and Canonaco M Morphological and functional variations of
Leydig cells in testis of the domestic pig during the different
biological stages of development. J Exp Zool 2000, 287:167-175
17. Mauduit C, Goddard I, Besset V, Tabone E, Rey C, Gasnier F,
Dacheux F and Benahmed M Leukemia inhibitory factor antago-
nizes gonadotropin induced testosterone synthesis in cul-
tured porcine Leydig cells: sites of actions. Endocrinology 2001,
142:2509-2520
18. Orava M, Haour F, Leinonen P, Ruokonen A and Vihko R Relation-
ships between unconjugated and sulphated steroids in por-
cine primary Leydig cell culture. J Steroid Biochem 1985, 22:507-
512
19. Forest M, Cathiard A and Bertrand J Total and unbound testo-
sterone levels in the newborns and normal hypogonadal chil-
dren: use of sensitive radio-immunoassay for testosterone. J
Clin Endocrinol Metab 1973, 36:1132-1142
20. Bernier M, Gibb W, Haour F, Collu R, Saez J and Ducharme J Studies
with purified immature porcine Leydig cells in culture. Biol
Reprod 1178, 29:1172-1983
21. Mauduit C, Gasnier F, Rey C, Chauvin MA, Stocco DM, Louisot P and
Benahmed M Tumor necrosis factor-α inhibits Leydig cell
steroidogenesis through a decrease in steroidogenic acute
regulatory protein expression.  Endocrinology 1998, 139:2863-
2868
22. Helboe L, Moller M, Norregaard L, Schiodt M and Stidsen C Devel-
opment of selective antibodies against the human somato-
statin receptor subtypes sst1–sst5. Brain Res Mol Brain Res 1997,
49:82-8
23. Hunyady B, Hipkin RW, Shonbrunn A and Mezey E Immunohisto-
chemical localization of somatostatin receptor sst2A in the
rat pancreas. Endocrinology 1997, 138:2632-2635
24. Mezey E, Hunyady B, Mitra S, Hayes E, Liu Q, Schaeffer J and Schon-
brunn A Cell specific expression of the sst2A and sst5 soma-
tostatin receptors in the rat anterior pituitary. Endocrinology
1998, 139:414-419
25. Lopez F, Esteve JP, Buscail L, Delesque N, Saint-Laurent N, Theveniau
M, Nahmias C, Vaysse N and Susini C The tyrosine phosphatase
SHP-1 associates with the sst2 somatostatin receptor and is
an essential component of sst2-mediated inhibitory growth
signaling. J Biol Chem 1997, 272:24448-24454
26. Hofland LJ, Liu Q, Van Koetsveld PM, Zuijderwijk J, Van Der Ham F,
Krijger RR, Schonbrunn A and Lamberts SWJ Immunohistochem-
ical detection of somatostatin receptor subtypes sst1 and
sst2A in human somatostatin receptor positive tumors. J Clin
Endocrinol Metab 1999, 84:775-780
27. Reubi JC, Laissue JA, Waser B, Steffen DL, Hipkin RW and Schonb-
runn A Immunohistochemical detection of somatostatin
sst2A receptors in the lymphatic, smooth muscular and pe-
ripheral nervous systems of the human gastrointestinal
tract: facts and artifacts. J Clin Endocrinol Metab 1999, 84:2942-
2950
28. Kubota A, Yamada Y, Kagimoto S, Shimatsu A, Imamura M, Tsuda K,
Imura H, Seino S and Seino Y Identification of somatostatin re-
ceptor subtypes and an implication for the efficacity of soma-
tostatin analogue SMS 201-995 in treatment of human
endocrine tumors. J Clin Invest 1994, 93:1321-1325
29. Hardy MP, Kelce WR, Klinefelter GR and Ewing LL Differenciation
of Leydig cell precursor in vitro: a role for androgen. Endo-
crinology 1990, 127:488-490
30. Purvis K, Calandra R, Naess O, Attramadal A, Torjesen PA and Hans-
son V Do androgens increase Leydig cell sensitivity to lutein-
izing hormone? Nature 265:169-170
31. Darney KJ and Ewing L Autoregulation of testosterone secre-
tion in perfused rat testes. Endocrinology 1981, 109:993-995
32. James R, Sarapura V, Bruns C, Raulf F, Dowding J, Gordon D, Wood
W and Ridgway E Thyroid hormone-induced expression of spe-
cific somatostatin receptor subtypes correlates with involu-
tion of the TtT-97 murine thyrotrope tumor.  Endocrinology
1997, 138:719-724
33. Xu Y, Song J, Berelowitz M and Bruno J Estrogen regulates soma-
tostatin receptor subtype 2 messengeer ribonucleic acid ex-
pression in human breast cancer cells.  Endocrinology 1996,
137:5634-5640
34. Djordjijevic D, Zhang J, Priam M, Viollet C, Gourdji D, Kordon C and
Epelbaum J Effects of 17-beta estradiol on somatostatin recep-
tor expression and inhibitory effects on growth hormone
and prolactin release in rat pituitary cell cultures. Endocrinolo-
gy 1998, 139:2272-2277
35. Xu Y, Berelowitz M and Bruno J Dexamethasone regulates so-
matostatin receptor subtype messenger ribonucleic acid ex-
pression in rat pituitary GH4C1 cells.  Endocrinology 1995,
136:5070-5075
36. Senaris R, Lago F and Dieguez C Gonadal regulation of somato-
statin receptor 1, 2 and 3 mRNA levels in thee rat anterior
pituitary. Mol Brain Res 1996, 38:171-175
37. Benahmed M Growth factors and cytokines in the testis. In:
Male infertility (Edited by: Comhaire FH) London, Chapman & Hall Medical
1996, 55-95
38. Guo F, Beaudet A and Shaffer-Tannenbaum G The effect of hypo-
physectomy and growth hormone replacement on sst1 and
sst2 somatostatin receptor subtype messenger ribonucleic
acids in the arcuate nucleus. Endocrinology 1996, 137:3928-3935